This inventor holds 1 USPTO granted patent. Top assignees: China Pharmaceutical University, Nanjing University of Chinese Medicine. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: He Tang: Innovator in Indole Alkaloid Research
Introduction
He Tang is a notable inventor based in Nanjing, China. He has made significant contributions to the field of pharmacology, particularly through his research on indole alkaloids. His work has implications for treating diabetic complications and protecting lung tissues.
Latest Patents
He Tang holds a patent for an indole alkaloid and its preparation method and use. The patent describes a compound represented by a specific formula, along with its pharmaceutically acceptable salts, metabolic precursors, metabolites, isomers, and prodrugs. Experimental results indicate that this indole alkaloid promotes axon growth in peripheral sensory neurons, improves nerve conduction velocity, and alleviates anesthesia symptoms in diabetic rats. Additionally, it aids in the healing of foot ulcer wounds in diabetic rats, demonstrating therapeutic effects on diabetic complication peripheral neuropathy and diabetic feet. Furthermore, the indole alkaloid significantly reduces pulmonary fibrosis induced by bleomycin in mice, showcasing its protective role in lung tissues.
Career Highlights
He Tang has worked at prestigious institutions such as Nanjing University of Chinese Medicine and China Pharmaceutical University. His research has garnered attention for its potential applications in medical treatments.
Collaborations
He has collaborated with notable colleagues, including Xu Shen and Sheng Jiang, contributing to advancements in his field.
Conclusion
He Tang's innovative work in indole alkaloid research highlights his commitment to improving therapeutic options for diabetic complications and lung protection. His contributions are paving the way for future advancements in pharmacological treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile